The contributions of muscarinic receptors and changes in plasma aldosterone levels to the anti-hypertensive effect of Tulbaghia violacea

BMC Complementary and Alternative Medicine

Kenechukwu Obikeze¹  Pierre Mugabo¹  Ismaila Raji² 

[1] School of Pharmacy, University of the Western Cape, Private Bag X17, Cape Town, 7535, South Africa;Faculty of Medicine, National University of Science and Technology, P.O. Box AC 939 Ascot, Bulawayo, Zimbabwe

关键词: Aldosterone;    Muscarinic receptors;    Heart rate;    Blood pressure;    Spontaneously hypertensive rats;    Tulbaghia violacea;   

Others  :  1231163
DOI  :  10.1186/1472-6882-13-13

 received in 2012-07-19, accepted in 2012-11-12,  发布年份 2013

【 摘 要 】

Background

Tulbaghia violacea Harv. (Alliaceae) is used to treat various ailments, including hypertension (HTN) in South Africa. This study aims to evaluate the contributions of muscarinic receptors and changes in plasma aldosterone levels to its anti-hypertensive effect.

Methods

In the acute experiments, methanol leaf extracts (MLE) of T. violacea (30–120 mg/kg), muscarine (0.16 -10 μg/kg), and atropine (0.02 - 20.48 mg/kg), and/or the vehicle (dimethylsulfoxide (DMSO) and normal saline (NS)) were respectively and randomly administered intravenously in a group of spontaneously hypertensive (SHR) weighing 300 to 350 g and aged less than 5 months. Subsequently, T. violacea (60 mg/kg) or muscarine (2.5 μg/kg) was infused into eight SHRs, 20 min after atropine (5.12 mg/kg) pre-treatment. In the chronic (21 days) experiments, the SHRs were randomly divided into three groups, and given the vehicle (0.2 ml/day of DMSO and NS), T. violacea (60 mg/kg/day) and captopril (10 mg/kg/day) respectively into the peritoneum, to investigate their effects on blood pressure (BP), heart rate (HR), and plasma aldosterone levels. Systolic BP and HR were measured using tail-cuff plethysmography during the intervention. BP and HR were measured via a pressure transducer connecting the femoral artery and the Powerlab at the end of each intervention in the acute experiment; and on day 22 in the chronic experiment.

Results

In the acute experiments, T. violacea, muscarine, and atropine significantly (p < 0.05) reduced BP dose-dependently. T. violacea and muscarine produced dose-dependent decreases in HR, while the effect of atropine on HR varied. After atropine pre-treatment, dose-dependent increases in BP and HR were observed with T. violacea; while the BP and HR effects of muscarine were nullified. In the chronic experiments, the T. violacea-treated and captropril-treated groups had signicantly lower levels of aldosterone in plasma when compared to vehicle-treated group. Compared to the vehicle-treated group, significant reduction in BP was only seen in the captopril-treated group; while no difference in HR was observed among the groups.

Conclusion

The results obtained in this study suggest that stimulation of the muscarinic receptors and a reduction in plasma aldosterone levels contribute to the anti-hypertesive effect of T. violacea.

【 授权许可】

   
2013 Raji et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

Figure 10.

Figure 11.

Figure 12.

Figure 13.

【 参考文献 】

• [1]Seedat YK: Impact of poverty on hypertension and cardiovascular disease in sub-Saharan Africa. Cardiovasc J Afr 2007, 18(5):316-320.
• [2]Murray CJL, Lopez AD, Health HSoP Organization WH Bank W: The Global burden of Disease a Comprehensive Assessment of Mortality and Disability from diseases, Injuries, and Risk Factors in 1990 and Projected to 2020; Summary. Cambridge, MA: Harvard School of Public Health on behalf of the World Health Organization and theWorld Bank; 1996.
• [3]Steyn K, Sliwa K, Hawken S, Commerford P, Onen C, Damasceno A, Ounpuu S, Yusuf S: Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation 2005, 112(23):3554.
• [4]Pieters M, Vorster HH: Nutrition and hemostasis: a focus on urbanization in South Africa. Mol Nutr Food Res 2008, 52(1):164-172.
• [5]van Rooyen JM, Huisman HW, Eloff FC, Laubscher PJ, Malan L, Steyn HS, Malan NT: Cardiovascular reactivity in Black South-African males of different age groups: the influence of urbanization. Ethn Dis 2002, 12(1):69-75.
• [6]Hinderliter AL, Blumenthal JA, Waugh R, Chilukuri M, Sherwood A: Ethnic differences in left ventricular structure: relations to hemodynamics and diurnal blood pressure variation. Am J Hypertens 2004, 17:43-49.
• [7]Suarez EC, Saab PG, Llabre MM, Kuhn CM, Zimmerman E: Ethnicity, gender, and age effects on adrenoceptors and physiological responses to emotional stress. Psychophysiology 2004, 41:450-460.
• [8]Lemogoum D, Seedat YK, Mabadeje AF, Mendis S, Bovet P, Onwubere B, Blackett KN, Lenfant C, Kabangu JR, Block P, et al.: Recommendations for prevention, diagnosis and management of hypertension and cardiovascular risk factors in sub-Saharan Africa. J Hypertens 2003, 21(11):1993-2000.
• [9]Seedat YK: Hypertension in developing nations in sub-Saharan Africa. J Hum Hypertens 2000, 14(10–11):739-747.
• [10]Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, Jamerson KA, Jones WE, Haywood J, Maxey R: Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003, 163(5):525-541.
• [11]Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42(6):1206-1252.
• [12]Good R: The Geography of Flowering Plants. 4th edition. London: Longman; 1974.
• [13]Goldblatt P, Manning JC: Cape Plants, A Conspectus of the Cape Flora of South Africa. Pretoria Strelitzia 9: National Botanical Institute of South Africa, South Afica and MBG Press, Missouri; 2000.
• [14]Cunningham AB: African medicinal plants: setting priorities at the interface between conservation and primary healthcare. People and Plants Working Paper 1. Paris: UNESCO; 1993.
• [15]Meyer JJM, Afolayan AJ, Taylor MB, Engelbrecht L: Inhibition of herpes simplex virus type 1 by aqueous extracts from shoots of Helichrysum qureonites. J Ethnopharmacol 1996, 52:41-43.
• [16]Mander M: Marketing of Indigenous Medicinal Plants in South Africa. A Case Study in KwaZulu-Natal. Rome: FAO; 1998.
• [17]McGaw L, JÃger A, Grace O, Fennell C, van Staden J, van Niekerk A: Medicinal plants. In Ethics in Agriculture An African Perspective. Dordrecht, The Netherlands: Springer; 2005:67-83.
• [18]MacDonald JA, Marchand ME, Langler RF: Improving upon the in vitro biological activity of antithrombotic disulfides. Blood coagul fibrinolysis: an international journal in haemostasis and thrombosis 2004, 15(6):447-450.
• [19]Van Wyk BE, Wink M: Medicinal plants of the world. Pretoria: Brazia Publications; 2004.
• [20]Bungu L, van de Venter M, Frost C: Evidence for an in vitro anticoagulant and antithrombotic activity in Tulbaghia violacea. Afr J Biotechnol 2008, 7(6):681-688.
• [21]Raji IA, Mugabo P, Obikeze K: Effect of Tulbaghia violacea on the blood pressure and heart rate in male spontaneously hypertensive Wistar rats. J Ethnopharmacol 2012, 140(1):98-106.
• [22]Ncube B, Finnie JF, Van Staden J: In vitro antimicrobial synergism within plant extract combinations from three South African medicinal bulbs. J Ethnopharmacol 2012, 139(1):81-89.
• [23]Ramesar S, Baijnath H, Govender T, Mackraj I: Angiotensin I-converting enzyme inhibitor activity of nutritive plants in KwaZulu-Natal. J Med Food 2008, 11(2):331-336.
• [24]Mackraj I, Ramesar S, Singh M, Govender T, Baijnath H, Singh R, Gathiram P: The in vivo effects of Tulbhagia violacea on blood pressure in a salt-sensitive rat model. J Ethnopharmacol 2008, 117(2):263-269.
• [25]Hearse DJ, Sutherland FJ: Experimental models for the study of cardiovascular function and disease. Pharmacol Res 2000, 41(6):597-603.
• [26]Wang GJ, Lin YL, Chen CH, Wu XC, Liao JF, Ren J: Cellular calcium regulatory machinery of vasorelaxation elicited by petasin. Clin Exp Pharmacol Physiol 2010, 37(3):309-315.
• [27]Lee YC, Ko YH, Hsu YP, Ho LT: Plasma leptin response to oral glucose tolerance and fasting/re-feeding tests in rats with fructose-induced metabolic derangements. Life Sci 2006, 78(11):1155-1162.
• [28]Giménez J, Garcia PM, Bonacasa B, Carbonell LF, Quesada T, Hernández I: Effects of oestrogen treatment and angiotensin‐converting enzyme inhibition on the microvasculature of ovariectomized spontaneously hypertensive rats. Exp Physiol 2006, 91(1):261-268.
• [29]Kurtz TW, Griffin KA, Bidani AK, Davisson RL, Hall JE: Recommendations for blood pressure measurement in humans and experimental animals: part 2: blood pressure measurement in experimental animals: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005, 45(2):299-310.
• [30]Khwanchuea R, Mulvany MJ, Jansakul C: Cardiovascular effects of tyramine: adrenergic and cholinergic interactions. Eur J Pharmacol 2008, 579(1–3):308-317.
• [31]Lessa MA, Araujo CV, Kaplan MA, Pimenta D, Figueiredo MR, Tibirica E: Antihypertensive effects of crude extracts from leaves of Echinodorus grandiflorus. Fundam Clin Pharmacol 2008, 22(2):161-168.
• [32]Rattmann YD, Crestani S, Lapa FR, Miguel OG, Marques MCA, da Silva-Santos JE, Santos ARS: Activation of muscarinic receptors by a hydroalcoholic extract of Dicksonia sellowiana Presl. HooK (Dicksoniaceae) induces vascular relaxation and hypotension in rats. Vascul Pharmacol 2008, 50(1–2):27-33.
• [33]De Menezes IAC, Moreira Í, De Paula JWA, Blank AF, Antoniolli AR, Quintans Júnior LJ, Santos MRV: Cardiovascular effects induced by Cymbopogon winterianus essential oil in rats: involvement of calcium channels and vagal pathway. J Pharm Pharmacol 2010, 62(2):215-221.
• [34]Katzung B, Masters S, Trevor A: Basic and Clinical Pharmacology 12/E. New York: McGraw-Hill Companies,Incorporated; 2011.
• [35]Brunton L, Chabner BA, Knollmann B: Goodman and Gilman's Pharmacological Basis of Therapeutics, Twelfth Edition (SET2). New York: McGraw-Hill; 2010.
• [36]Fraser PJ: Pharmacological actions of pure muscarine chloride. Br J Pharmacol Chemother 1957, 12(1):47-52.
• [37]Bartholow R: Title A Practical Treatise On Materia Medica And Therapeutics. 11th edition. New York: Appleton And Company; 1908.
• [38]Wess J, Lambrecht G, Mutschler E, Melchiorre C, Angeli P: Selective blockade in vivo of cardiac muscarinic M2 receptors by a polymethylene tetramine, BHC-9C. Eur J Pharmacol 1987, 142(3):475-478.
• [39]Lazartigues E, Brefel-Courbon C, Tran MA, Montastruc JL, Rascol O: Spontaneously hypertensive rats cholinergic hyper-responsiveness: central and peripheral pharmacological mechanisms. Br J Pharmacol 1999, 127(7):1657-1665.
• [40]Mestivier D, Dabire H, Chau NP: Effects of autonomic blockers on linear and nonlinear indexes of blood pressure and heart rate in SHR. Am J Physiol Heart Circ Physiol 2001, 281(3):H1113-1121.
• [41]Abraham S, Cantor EH, Spector S: Studies on the hypotensive response to atropine in hypertensive rats. J Pharmacol Exp Ther 1981, 218(3):662-668.
• [42]Abraham S, Cantor EH, Spector S: Atropine lowers blood pressure in normotensive rats through blockade of [alpha]-adrenergic receptors. Life Sci 1981, 28(3):315-322.
• [43]Cantor EH, Abraham S, Marcum EA, Spector S: Structure-activity requirements for hypotension and [alpha]-adrenergic receptor blockade by analogues of atropine. Eur J Pharmacol 1983, 90(1):75-83.
• [44]Rossier BC, Schild L: Epithelial sodium channel mendelian versus essential hypertension. Hypertension 2008, 52(4):595-600.
• [45]Dauphinot V, Gosse P, Kossovsky MP, Schott A-M, Rouch I, Pichot V, Gaspoz J-M, Roche F, Barthelemy J-C: Autonomic nervous system activity is independently associated with the risk of shift in the non-dipper blood pressure pattern. Hypertens Res 2010, 33(10):1032-1037.
• [46]Joyner MJ, Charkoudian N, Wallin BG: Sympathetic nervous system and blood pressure in humans. Individualized Patterns of Regulation and Their Implications. Hypertension 2010, 56(1):10-16.
• [47]Ishii M, Kurachi Y: Muscarinic acetylcholine receptors. Curr Pharm Des 2006, 12(28):3573-3581.
• [48]Touma F, Chew V, Chua W, Jelinek H, Wong P, Spence I, McLachlan C: Chronic high dose captopril decreases total heart rate variability and increases heart rate in C57BL/6 J mice. Int J Cardiol 2009, 136(2):211-213.
• [49]Shin CY, Choi WS, Yi I, Nan MH, Myung CS: Synergistic decrease in blood pressure by captopril combined with losartan in spontaneous hypertensive rats. Arch Pharm Res 2009, 32(6):955-962.
• [50]Zicha J, Dobesova Z, Kunes J: Late blood pressure reduction in SHR subjected to transient captopril treatment in youth: possible mechanisms. Physiol Res / Academia Scientiarum Bohemoslovaca 2008, 57(3):495-498.
• [51]Hashimoto H, Hiwada K, Kokubu T: Effects of a single administration of captopril on hemodynamics and serum angiotensin converting enzyme activity, plasma renin activity and plasma aldosterone concentration in hypertensive patients. Jpn Circ J 1981, 45(2):176.
• [52]Ajayi A, Campbell B, Meredith P, Kelman A, Reid J: The effect of captopril on the reflex control heart rate: possible mechanisms. Br J Clin Pharmacol 1985, 20(1):17.
• [53]Imai Y, Abe K, Sato M, Haruyama T, Hiwatari M, Goto T, Sato K, Kasai Y, Tajima J, Yoshinaga K: Evaluation of the chronotropic property of captopril in hypertensive patients. Am Heart J 1982, 104(6):1339-1345.
• [54]Sturani A, Chiarini C, Degliesposti E, Santoro A, Zuccala A, Zucchelli P: Heart rate control in hypertensive patients treated by captopril. Br J Clin Pharmacol 1982, 14(6):849.
• [55]Grassi G, Arenare F, Quarti-Trevano F, Seravalle G, Mancia G: Heart rate, sympathetic cardiovascular influences, and the metabolic syndrome. Prog Cardiovasc Dis 2009, 52(1):31-37.
• [56]Grassi G: Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 2009, 54(4):690-697.
• [57]Connell JMC, Davies E: The new biology of aldosterone. J Endocrinol 2005, 186(1):1-20.
• [58]Whaley-Connell A, Johnson MS, Sowers JR: Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis 2010, 52(5):401-409.
• [59]Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Koch WJ: Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels. J Am Coll Cardiol 2011, 57(3):356-365.
• [60]Briet M, Schiffrin EL: Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 2010, 6(5):261-273.